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Delayed presentation for antiretroviral therapy (ART) care is common in sub-Saharan Africa, with 
most patients accessing care when immunocompromised and a high proportion dying in their first 
year of ART. These shortcomings are hindering the success of ART programmes, and solutions to 
mitigate this problem, lie further upstream between the interval of HIV testing and ART initiation.  
The aim of the literature review (Part B) was to assess retention and linkage at each stage between 
HIV testing and ART initiation and to identify risk factors, barriers and facilitators influencing each 
stage between this interval. 
Timely entry into HIV/ART care is crucial to achieve maximum health benefits for the patient and 
healthcare system. The aim of the research study (Part C) was to assess the proportion and 
characteristics of newly-diagnosed HIV+ patients who received their laboratory CD4 count result 
and accessed HIV care after testing HIV+ at a mobile testing unit as well as to examine barriers to 
HIV care. The study was based on the hypothesis that linkage to care among HIV+ individuals with 
lower CD4 counts would be better in comparison to those with higher CD4 counts. The protocol 
(Part A) outlines the study design and procedures. 
Findings from the literature review (Part B) indicated that substantial attrition occurred at all steps 
between the interval of HIV testing and ART initiation. The first major drop-out occurred at the point 
of linkage from a HIV testing site to a medical facility for ongoing care. The next loss occurred 
between CD4 count testing and collection of the test result. Moreover, this review found that less 
than half of the patients not yet eligible for ART were retained in pre-ART care (range: 42%-45 %) 
and nearly two-thirds of ART-eligible patients linked to ART care (median: 67%, IQR 58-81). 
Results from the study (Part C) showed that forty-three (27%) individuals did not receive their CD4 
count result. A lower CD4 count, being female and the availability of a phone number increased the 
likelihood of receiving this result. Linkage to care was 100% in patients with CD4 counts ≤ 200 
cells/µl, 66.7% in individuals with CD4 counts of 201-350 cells/µl and 36.4% in those with CD4 
counts > 350 cells/µl. A lower CD4 count, disclosure, presence of TB symptoms and unemployment 
increased the likelihood of linking to care. The most common stated barrier (41.4%) to linking to 
care was the inability to access public healthcare facilities during working hours. 
Interventions such as structured referral systems, transport vouchers, community escorts, point of 
care (POC) CD4 count testing and effective post-test counselling could reduce drop-out between 
HIV-testing and ART initiation. Linkage to care was best among those eligible for ART. Interventions 




































Note to examiner: Only data forms pertaining to the study have been 
presented in the Appendix. Data forms used by the mobile unit have not been 
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The aim of this study is to investigate the linkage of newly-diagnosed HIV positive clients from a 
mobile testing unit (Tutu Tester) to HIV care at public healthcare facilities as well as to investigate 
the reasons for not linking to care. 
OBJECTIVES 
The primary objectives are to 1) determine the proportion of newly-diagnosed HIV positive clients 
who were assessed for antiretroviral therapy (ART) eligibility and received their laboratory CD4 
count result from the mobile unit, 2) measure the proportion of newly-diagnosed HIV positive clients 
that accessed a primary healthcare facility, 3) document the proportion of newly-diagnosed HIV 
positive clients eligible for ART that subsequently started ART and 4) to establish the median time 
from diagnosis to entry into care for ART-eligible clients and clients not yet eligible for ART. 
Furthermore, the secondary objective is to investigate the reasons for not linking to care. 
 
STUDY DESIGN 
This is a prospective observational cohort study which will involve following up (telephonically or 
home visits) clients that were newly-diagnosed with HIV within the Cape Metropolitan district, 
between August 2008 and December 2009, and successfully contacted to receive their laboratory 
CD4 count result. Client records of all potentially eligible participants will be reviewed by staff 
subsequent to obtaining informed con ent. Participants will undergo a brief questionnaire session 
and thereafter a clinic folder review will be conducted on patients that linked to care and provided 




















PART I) INTRODUCTION 
1.1) Background 
The generalised HIV/AIDS epidemic in South Africa has undoubtedly reached catastrophic levels. 
HIV prevalence in adults aged 15-49 was estimated to be 18.1% in 2008 in South Africa. 1 
Remarkable progress has been made with regards to antiretroviral therapy (ART) roll-out in 
resource-limited settings. 2 However, in 2007 an estimated 350 000 deaths were attributable to 
HIV/AIDS in South Africa. 1 Delay of ART initiation is thought to result in high HIV associated 
mortality and morbidity. 3 Hence efforts to ensure that HIV-infected individuals initiate care and 
treatment promptly are vital to achieve better outcomes.  
 
1.2) HIV testing and counselling: A gateway to prevention, care, treatment and support 
HIV testing and counselling should be the entry point to a continuum of HIV care. The South African 
National Strategic Plan aims to provide access to appropriate packages of care, treatment and 
support to 80% of all the people diagnosed with HIV by 2011 in order to reduce mortality and 
morbidity. 4 According to South Africa’s HIV/AIDS Operational Plan, once an individual is diagnosed 
with HIV, assessment for ART eligibility including a CD4 count and clinical staging should follow 
promptly. 5 HIV-infected individuals who are not yet eligible for ART should be advised to enter 
comprehensive HIV care whereas those with a laboratory CD4 count <200 cells/µl or clinical stage 4 
should be referred for starting ART. 5 Once HIV-infected individuals have had their first contact with 
the primary healthcare facility they should enter a continuum of care which might include ART 
and/or Cotrimoxazole, regular screening for cervical cancer, intensified tuberculosis (TB) case 
finding and contraceptives. 
Limited data investigating the proportion of newly-diagnosed HIV infected individuals assessed for 
ART eligibility 6 and the proportion of ART-eligible individuals promptly starting ART is available.7 A 
recent study looking at routinely collected data from HIV testing and treatment facilities in 
Mozambique showed that of the 1506 adults eligible for ART, only 471 (31.3%) started ART. 8  A 
study conducted in South Africa found that of the 501 patients eligible for ART in an urban hospital 
setting; only 408 patients (81.4%) were in care and on ART at 3-month follow-up in Durban .7 A 
study conducted in Cape Town in 2006 concluded that only 60% of newly-diagnosed HIV positive 
clients had a CD4 count within 6 months of diagnosis. 6 In contrast, loss to follow-up in ART cohorts 
is well described. To date, several studies from sub-Saharan Africa have documented a substantial 
early loss to follow-up and mortality of patients in ART programmes 9 but only a few studies have 














1.3) Justification and Hypothesis 
There is a paucity of published studies from resource-limited settings investigating the linkage of 
newly-diagnosed HIV positive individuals to comprehensive HIV care. Furthermore, the linkage of 
HIV testing and care in mobile testing settings is an area of research that remains to be explored. 
The impetus for undertaking this research is to fill this gap and provide insight in the link to HIV care 
and treatment at primary healthcare facilities after accessing a mobile testing service.  
The Tutu Tester has been in operation for more than 18 months. The service is ongoing. It is our 
belief that this service could be enhanced if we knew the extent of linkage to care by clients who 
test positive for HIV. It is our hypothesis that this may be relatively good in patients with low CD4 
counts or concomitant disease but less good in patients who are earlier in their infection. The 
client’s stage of infection at diagnosis is graphically presented to him/her during post-test 
counselling using a colour coding system on a Road to HIV Health card that is offered to all clients. 
It would be important to know this baseline data in order to devise more intensive methods to 
improve linkage to care. This is particularly important with the prospect of earlier ART.  
 
1.4) Study Site: The Tutu Tester 
The Tutu Tester project is a mobile testing service managed by the Desmond Tutu HIV Foundation 
(DTHF). Apart from HIV testing and counselling, the Tutu Tester also offers diagnostic services for 
other conditions (i.e. hypertension, diabetes, obesity, TB, pregnancy) in an effort to normalise HIV 
testing. The Tutu Tester operates in and around the Cape Peninsula, in co-operation with the City of 
Cape Town and Provincial Health Authorities, usually at taxi ranks, shopping centres, other 
community facilities and along roadside. All services offered by the Tutu Tester are free of charge.  
Each client accessing the mobile is first registered manually, providing only their date of birth, 
gender and initials. Thereafter the client’s information is registered electronically and additional 
details such as residential suburb, nationality and cell phone number are stored. The client’s 
fingerprint is also captured using the biometric system to facilitate access to their medical records at 
a subsequent visit. This electronic system generates a client code which is assigned to the 
individual. This code consists of four letters (indicating the site that the client was tested at) and a 
four digit number (sequential at each site). All personal details supplied by the client are voluntary 
and refusal does not influence client care in any manner. However, should the need arise only 
clients that give the Tutu Tester staff permission to be contacted are traced. Following registration 












performs the HIV test, documents the medical history and measures the client’s blood pressure and 
blood glucose. 
The HIV testing model used by the Tutu Tester is client-initiated counselling and testing, in 
accordance with the provincial Advise, Consent, Test and Support (ACTS) policy. All clinical nurse 
practitioners and counsellors of the Tutu Tester have been trained in ACTS. Clients who consent to 
HIV testing undergo a rapid HIV test (Bioline HIV-1/2 3.0, Standard Diagnostics, Korea). A rapid 
confirmatory test (Determine HIV-1/2, Abbott Laboratories) is only performed if the first rapid test 
produces a positive result. Clients who test negative are subsequently tested for all other conditions 
and then undergo risk reduction counselling. Moreover referral letters are given to clients to take to 
their nearest healthcare provider if necessary. Clients who test positive are staged according to the 
World Health Organisation (WHO) staging manual. In addition, CD4 count testing is offered. This 
entails drawing a sample of blood which is then sent to Toga Laboratory in Gugulethu. Once an HIV 
test is done, the client undergoes testing for all the other conditions offered. 
Furthermore, all HIV positive individuals, those with symptoms of TB and randomly selected 
individuals are asked to consent to doing an induced sputum sample as part of a study investigating 
active case finding (Rec Ref 502/2008). Induced sputum samples for TB testing are sent to the 
National Health Laboratories (NHLS) at Groote Schuur Hospital. 
Thereafter HIV positive clients are given a referral letter to take to their healthcare provider together 
with a Road to HIV Health Card. The Road to HIV Health Card was designed by the DTHF and the 
Tutu Tester project in order to assist positive clients and nurses at their clinics with the virologic and 
immunologic monitoring of this disease by plotting viral loads together with the client’s CD4 counts. 
Thus the primary aim of this intervention is to assist HIV positive clients in taking the responsibility of 
personally keeping track of their health condition. 
When laboratory CD4 counts become available (usually within 72 hours) clients are contacted 
telephonically with their results and later with TB results. If contact numbers are unavailable either a 
home visit is done or a letter is sent to the address provided by the client, requesting the client to 
contact the Tutu Tester for their results. Once contact is made, the laboratory CD4 result is given 
and implications discussed. All HIV positive clients are requested to document their laboratory CD4 
count result on their Road to HIV Health Card and encouraged to attend clinics for either 
comprehensive HIV care or to start ART if eligible, as well as other health services if necessary. In 
addition, clinics are also requested to contact the Tutu Tester for laboratory results. This follow-up 














1.5) Study Aims and Objectives 
1.5.1) Aims 
The aim of this study is to investigate the linkage of newly-diagnosed HIV positive clients from a 
mobile testing unit to HIV care at public healthcare facilities as well as to investigate the reasons for 
not linking to care. 
 1.5.2) Objectives 
 Primary Objectives 
1) To determine the proportion of newly-diagnosed HIV positive clients that received their 
CD count result from the mobile service. 
2) To determine the proportion of newly-diagnosed HIV positive clients that received their 
CD count result and accessed a health care facility for respective care. 
 
 Secondary Objectives 

































PART II) METHODS 
2.1) Study Design 
This is a prospective observational cohort study which will focus on Tutu Tester clients who were 
newly-diagnosed with HIV within the Cape Metropolitan district between August 2008 and 
December 2009 and successfully contacted to receive their laboratory CD4 count result. The period 
of follow-up is three months, April to June 2010. This process will involve obtaining informed 
consent, followed by the administration of a semi-quantitative questionnaire, either telephonically or 
face-to face, as well as contacting clinics to verify attendance. 
2.2) Population and Sampling 
2.2.1)  Description of the population 
The study will follow a cohort of Tutu Tester clients that were newly-diagnosed with HIV within the 
Cape Metropolitan area between August 2008 and December 2009 and successfully contacted to 
receive their laboratory CD4 count result. A major limitation in this study is the exclusion of newly-
diagnosed HIV positive clients that were unable to be contacted from this cohort. This decision was 
taken as these clients did not receive feedback from the Tutu Tester on their assessment for ART 
eligibility based on a laboratory CD4 count result either due to laboratory error or because the Tutu 
Tester staff were unable to contact them. 
 
 Inclusion Criteria 
 Newly positive HIV test performed at the Tutu tester between August 2008 and 
December 2009 within the Cape Metropolitan area 
 Available laboratory CD4 count result 
 Successfully contacted to receive laboratory CD4 count result 
 Aged 18 years or older 
 Able and willing to provide informed consent 
 
 
 Exclusion Criteria 
 Known HIV positive clients  
 Aged less than 18 years old 
















2.2.2) Sampling strategy, sample size and justification for sample size 
The sample size for potentially eligible participants is 225. This estimate was ascertained from the 
Tutu Tester Access database and represents all Tutu Tester clients that were newly-diagnosed with 
HIV within the Cape Metropolitan area between August 2008 and December 2009 and successfully 
contacted to receive their laboratory CD4 count result.  Stratification of this sample size according to 
laboratory CD4 count results reveals the following, 29 clients with CD4 counts less than 200 cells/µl, 
48 clients with CD4 counts between 200-350 cells/µl and 148 clients with CD4 counts greater than 
350 cells/µl. All clients with CD4 counts below 350 cells/µl will be included in this study. A random 
sample of 80 clients will be selected from the 148 clients with CD4 counts above 350 cells/µl due to 
budget constraints, a short study time period and feasibility. Hence the estimated sample size for 
this study is 157. 
The majority of newly-diagnosed HIV+ individuals diagnosed on this mobile unit have CD4 counts > 
351 cells/µl. 10 It is logistically unfeasible to follow-up all potentially eligible patients in the > 351 
cells/µl CD4 count stratum within 3 months and thus a random sample (30%) will be drawn from this 
stratum. The proposed relatively small sample size in the < 200 cells/µl stratum  and 201-350 
cells/µl stratum is logistically manageable to follow-up within 3 months and thus it was decided that 
a 100% of individuals with laboratory CD4 counts ≤ 350  and 30% of individuals with laboratory CD4 
counts > 350 cells/µl will be sampled. 
 
2.3) Procedure 
The Tutu Tester database, client forms, referral letters and follow-up forms will be used to retrieve 
specific information of all potentially eligible participants for the Client Form Reviews (Appendix 2). 
Thereafter these participants will be contacted to determine if they are willing to participate in this 
study and provide informed consent (Appendix 1). Up to 3 attempts will be made to contact the 
client. Where no telephone number is available, a home visit will be done. All participants providing 
informed consent will subsequently undergo a semi quantitative questionnaire session (Appendix 3). 
Note follow-up (telephonic and home visits) will be conducted in accordance with the Tutu Tester’s 
Standard Operating Procedures (SOPs) for follow-up. Clinics will then be contacted to verify 
information supplied only by those participants who consent to this additional process (Appendix 1) 
and these details will be documented in the Clinic Attendance Form (Appendix 4). 
2.4) Data collection and monitoring 
Client data for each participant will be retrieved from the Tutu Tester Access database and 












Form Review (Appendix 2), Questionnaire (Appendix 3) and Clinic Attendance Form (Appendix 4) 
will be quality controlled and subsequently double-entered onto an electronic database, EpiData. 
This database will be checked regularly for inconsistencies.  
2.5) Staff  
This research is being conducted by the staff running the Tutu Tester. The staff member primarily 
concerned is a PEPFAR fellow who is also reading for a Masters in Public Health and will 
investigate this subject for her thesis. Her work commitment on the Tutu Tester team involves 
quality control of data forms as well as obtaining laboratory CD4 count results and ensuring results 
are returned to positive clients.  
An HIV/AIDS counsellor from  the Tutu Tester Project will undertake the role of field worker for this 
study as this individual possesses adequate experience in adherence counselling, following-up 
(home visits and telephonically) of HIV positive clients and is well trained in Good Clinical Practice 
(GCP). The field worker will possess a good understanding of the protocol, study methodology and 
the importance of consent. The Masters student will conduct interviews with all clients wishing to 








































Yes or No 
 
A client that successfully 
received his/her laboratory 
CD4 count result from the 
Tutu Tester via the following 
methods: telephonically, 
face-to-face, via a clinic 
 
 Tutu Tester 
database, client 
and follow-up form 
 Client Form 
Review 
 
• Accessed care 
 
Categorical: 
 Binary  
Yes or No 
 
A participant that initiated 
care by attending a primary 
healthcare facility at least 
once after being tested on 
the Tutu Tester. 
 
 Questionnaire 
 Clinic Attendance 
Form 
 




Yes or No 
 
A participant that had visited 
a primary healthcare facility 
more than once in the last six 
months and is either in 
routine HIV care or 
commenced ART. 
 
 Client Form 
Review 
 Questionnaire 
 Clinic Attendance 
Form 
 
• Eligible for ART 




Yes or No 
 
A participant that had a 
laboratory CD4 count result 
of  <200 cells/µl or clinical 
stage of 4 and is taking 
antiretrovirals (ARVs) 
 
 Client Form 
Review 
 Questionnaire 
 Clinic Attendance 
Form 
 
• Not eligible for 






Yes or No 
 
A participant that did not 
have a  laboratory CD4 count  
result of <200 cells/µl or 
clinical stage of 4 and is 
currently in routine HIV care 
and treatment (i.e. any of the 
following:  had a CD4 count 
in the past 6 months, on 
Bactrim (Co-trimoxazole) 
and/ or INH prophylaxis, 
screened for TB/STIs, if 
female, had a pap smear in 
the last 6 months) 
 
 Client Form 
Review 
 Questionnaire 
 Clinic Attendance 
Form 
 




Yes or No 
 
A participant that did not visit 
a primary healthcare facility 
after the Tutu Tester follow-
up for purposes of HIV care. 
 
 Client Form 
Review 
 Questionnaire 














2.7) Facilitation of clinic site preparation and participation 
Several major clinics within the Cape Metropolitan region (i.e. Hout Bay Main Road Clinic, 
Masiphumelele Clinic, Vuyani Clinic, Nyanga Clinic, Lotus River Clinic, and KTC Clinic) are likely to 
be involved in this study as they are the Tutu Tester’s main referral sites. Support from clinics is 
essential in order to access patient records for completion of this study’s Clinic Attendance Form. 
Prior to contacting clinics, clinic managers will be issued with the study’s protocol and requested to 
contact us if they have any queries relating to the clinic’s involvement. More importantly, to minimise 
any disruption on facility functioning the clinic manager will be requested to schedule appointments 
for the study staff to contact the clinic clerk in order to retrieve the necessary information from 
patient folders. No information other than what is needed to complete the Clinic Attendance form will 




























PART III) ANALYSIS 
3.1) Statistical Analysis 
Data will be statistically analysed using Stata (Version 10.0, College Station, Texas, USA). All 
participants will be stratified according to laboratory CD4 count results (<200 cells/µl, 200-350 
cells/µl, >350 cells/µl). Data will first be explored using simple tabulation and chi square statistics. 
The following proportions will be tabulated for each stratum: 
1) The proportion of newly-diagnosed HIV positive Tutu Tester clients who were assessed for ART 
eligibility and received their laboratory CD4 count result from the mobile unit. 
2) The proportion of newly-diagnosed HIV positive Tutu Tester clients that accessed a primary 
healthcare facility. 
3) The proportion of newly-diagnosed HIV positive Tutu Tester clients eligible for ART that 
subsequently started ART. 
4) The median time from diagnosis to entry into care for ART-eligible clients and clients not yet 
eligible for ART. 
 
The following variables (i.e. age, sex, referral for other services, TB symptoms) will be tabulated 
against the outcome variables (receipt of laboratory CD4 count result and linkage to care) and 
compared across the three strata. Participants eligible for ART will be compared to those not yet 
eligible for ART. The association between linkage to care and possible determinants (i.e. age, sex, 
clinical staging, employment status, participant’s perception of health status) will be determined 
using chi-square tests. The time from diagnosis to entry into care among ART-eligible clients and 
clients not yet eligible for ART will be assessed using medians and interquartile ranges. 
Initial analysis will use bivariate predictors of receipt of laboratory CD4 count result and linkage into 
care, with variables significant at the p<0.05 level entered into a multivariate logistic regression 



















Part IV) ETHICS AND COMMUNICATION 
HUMAN SUBJECTS PROTECTION 
All the procedures described here will be reviewed by the University of Cape Town Research Ethics 
Committee.  
4.1) Information Sheet and Informed Consent Forms 
The translated versions of these forms will be checked to verify all information before conducting 
any study procedures. Potential eligible participants will be contacted either telephonically or face-
to-face to obtain informed consent (Appendix 1) which will be provided in the language understood 
by the prospective participant (English or Xhosa). Refusal to give additional consent to the 
verification process will not affect the participant’s rights. This study adheres to the declaration of 
Helsinki 2000. 
4.2) Subjects Confidentiality 
Every effort will be put in place to maintain participant’s confidentiality. This study will manage 
potentially sensitive issues, such as confidentiality by conducting follow-ups in accordance with the 
Tutu Tester SOP. Individual identifiers such as names will be stripped off all forms (i.e. Client Form 
Reviews, Questionnaires, and Clinic Attendance Forms). These forms will be identified by the 
participants study numbers and stored in locked file cabinets with restricted access at the Tutu 
Tester office in Silvertown, Cape Town. Forms with personal identifiers such as the Informed 
Consent will be stored in a similar fashion yet in a separate cabinet. Furthermore, the database will 
be stored on a data server located at the DTHF, secured with a password to limit access. 
Confidentiality agreements will be signed by personnel authorised to access records.  
4.3) Potential Risk 
A foreseeable harm could be the loss of participant’s confidentiality. All personnel involved in this 
study will ensure that measures which minimize this risk will be maintained at all times. Participants 
may feel uncomfortable to be either visited at home or contacted telephonically. However, all study 
procedures will be conducted in the participants preferred method of contact. This study will in no 
way alter the clinical management of participants. 
4.4) Dissemination and Implementation of Research Findings 
The work will be prepared by the Masters student’s for her thesis submission to the University of 
Cape Town- Department of Public Health and Family Medicine. A summary of findings will be 
disseminated to the respective clinics involved in this study. Furthermore, a full final report will be 












Department of Health. In addition, a research paper will be submitted for publication to a peer-
reviewed medical journal and abstracts will be submitted to conferences. 
Our main intention is to use the results from this study to devise a new model aimed at assisting HIV 
infected individuals link to care more efficiently if indeed the study shows inadequate linkage to care 
in the present model.  The data, specifically reasons participants give for not linking to care, will 
provide us with the insight needed for designing this model, which we plan to pilot in the next phase 




































PART V: LOGISTICS 
5.1) Timetable 
 
PHASE AND PERIOD ACTIVITIES 
 
PHASE 1:  PREPARATION 
 MARCH 2010 
 
 Translate the information sheet and 
informed consent to Xhosa and verify 
translated version. 
 Print data forms  
 Set up data base  
 Prepare fieldworker for study  
 Create a list of potentially eligible 
participants 
 
PHASE 2: FIELD WORK 
 APRIL –JUNE 2010 
 
 Follow-up on clients  
 Contact clinics 
 
PHASE 3: DATA ENTRY AND ANALYSIS 
 JULY-SEPTEMBER 2010 
 
 Quality control forms 
 Enter data onto EpiData 
 Verify accuracy of data entered 
 Statistically analyse data 
PHASE 4: WRITE-UP 
 OCTOBER-DECEMBER 2010 
 
 Write-up 
 Submit draft to supervisor and co-
supervisor by December 
PHASE 5: EDITING 
 JANUARY 2011 
 
 Edit necessary changes to paper 
PHASE 6: DISSEMINATION OF RESULTS 
 FEBRUARY- APRIL 2011 
 
 
 Submission of thesis  
 Submission of full research report to City of 
Cape Town Health Department as well as 
the Western Cape Provincial DOH 
 Submission of summary of findings to 
clinics involved 
 Submission of research paper to peer 
reviewed medical journals and abstract to 
conferences 
PHASE 7: IMPLEMENTATION OF RESULTS 
 MAY –JUNE 2011 
 
 Devise new model if applicable 

















This study will be funded by the foundation’s French AID budget. 
 Currency (ZAR) 
PERSONNEL:  
Fieldworker (4500 x 3 months) 13 500 
Personnel - Subtotal 13 500 
  
OTHER:  
Translation ( 1 x Information Sheet & Informed Consent Form) 1000 
Printing ( 1 x Information Sheet & Informed Consent Form, 1 x 
Client Form Review, 3 x Questionnaire, 1 x Clinic Attendance form 
@ 40 cents per pg) 
500 
 
Fuel (750 x 3 months) 2 250 
Telephone/ Cell phone costs (1500 x 3 months) 4500 
Local office costs (300 x 4 months)  1200 
Other - Subtotal  9450 
  
SUBTOTAL  22 950 
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Note to examiner: This literature review was updated during the course of this year 
as new studies around this topic were recently published. Findings from my study 
(Part C) were presented at the 18th Conference on Retroviruses and Opportunistic 
Infections (CROI), February 2011. The published conference abstract was included 
in the literature review (Part B) and in theory should be presented after my article 
(Part C). However, my literature review (Part B) is presented before the article (Part 
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Sub-Saharan Africa continues to have the highest HIV/AIDS prevalence in the world with an 
estimated 22.5 million HIV-infected adults and children.1 This region’s generalised epidemic 
warranted rapid scale-up of HIV testing and antiretroviral therapy (ART) and thus by 2004 roll-out of 
testing sites and ART programmes commenced..2 Despite the gains in expanded services, ART 
coverage remains considerably low (37%).2 Furthermore, delayed presentation for ART care is 
common, with patients accessing care when immunocompromised and between 8%-26% of 
patients dying in their first year of ART.3 These shortcomings are hindering the success of ART 
programmes, and solutions to mitigate to this problem, lie further upstream between the interval of 
HIV testing and ART initiation.3 
The HIV cascade (i.e. the process between HIV testing through to ART initiation) is a synchronised 
pathway with a series of intermediate steps (Fig 1A). It begins with an HIV+ diagnosis, followed by 
completion of CD4 count testing and clinical staging.4 Patients that meet the ART eligibility criteria 
usually enrol into a treatment readiness programme before commencing ART.4 Those patients that 
are above the ART eligibility threshold (ART-ineligible) should enrol in a wellness programme and 
must remain in pre-ART care until they meet the ART-eligibility criteria. 4 This HIV cascade requires 
a well co-ordinated health system to facilitate linkage to care. However, in resource-constrained 
settings, inadequate healthcare systems frequently impede on a patient’s transition through the 
system and thus attrition along this pathway is inevitable. Losses can readily occur at the point of 
baseline CD4 count testing, pre-ART or ART care enrolment, pre-ART retention and ART initiation. 
For patients testing at non-healthcare facilities drop-out can occur further upstream (i.e. between an 
HIV+ test result and registration at an HIV clinic for follow-up care) (Fig 1B).  
Results from a recent mathematical modelling study suggests that retention of ART-ineligible 
patients in pre-ART care will be beneficial for resource-poor setting as it could increase the average 
life-years saved.5 Thus quantifying the magnitude of attrition at every stage of the cascade is crucial 
for determining where interventions should be targeted to improve retention. A deeper insight into 
the factors impeding a patient’s flow through the system is valuable for informing the design of these 
interventions. 
To this end, the aim of this review is to assess each stage of the HIV cascade. The objectives are 
to: 1) describe the proportion of eligible HIV+ patients retained in the appropriate form of care at 
each stage (Fig 1A): a. enrolled in HIV care following an HIV+ diagnosis, b. underwent CD4 count 












ART care if ART-ineligible and e. initiated ART if ART-eligible, 2) highlight risk factors associated 
with retention or attrition at each stage and 3) synthesise barriers and facilitators along the cascade. 
2) METHODS 
2.1) Criteria for selection of studies 
The aim of the search strategy was to identify all studies reporting on the proportion of HIV+ 
patients at any one of the steps between HIV testing and ART initiation (i.e. the proportion of 
individuals that registered at a medical facility following an HIV+ test result, underwent baseline CD4 
count testing following enrolment, received CD4 count results following CD4 testing as well as the 
proportion of ART-ineligible patients who were retained in pre-ART care and the proportion of ART-
eligible patients that initiated ART) (Fig 1A-B). All studies reporting on risk factors, barriers and 
facilitators of linkage to HIV care through to ART initiation were also gathered. Barriers were defined 
as any reason for drop-out from the cascade whereas facilitators were defined as any intervention 
shown to link or retain patients along the cascade. 
Studies were omitted if they: examined steps downstream from ART initiation (such as retention or 
adherence), were based on the private healthcare sector and were editorials or case-reports. 
Studies that were found to be of poor methodological quality were excluded. No restriction was 
placed on sample size. The search was limited to studies conducted within sub-Saharan Africa 
which were published in English between 2000 (the time when ART first became available in this 
region) 2 till the search end period (May 2011).  
 
2.2) Search strategy 
Two electronic databases (MEDLINE and Global Health) were comprehensively searched using a 
compound search strategy (Fig 2).  
Keyword searches were then performed in Africa-Wide Information and Google Scholar. Thereafter 
reference lists of eligible studies were searched to ensure relevant papers were not missed. A 
keyword search was then performed in the dissertation database of the University of Cape Town to 
identify unpublished work. 
Conference abstracts were sought through online abstract databases of the Conference on HIV 
Pathogenesis and Treatment of the International AIDS Society (IAS, 2001-2009), the Conference on 
Retroviruses and Opportunistic Infections (CROI, 2006-2011), the International AIDS Conference 












were contacted for recommended literature. A recently conducted systematic review was also used 
to identify relevant references.6 
 
2.3) Study selection, data extraction and quality assessment 
The citation manager, RefWorks, was used to download, remove duplicate citations and organise 
studies from search results. These studies were then screened by title and abstract according to the 
inclusion and exclusion criteria. After the first screening, the full article of all studies considered 
potentially eligible were retrieved and further reviewed for eligibility whereas conference abstracts 
were screened first by title, then by full abstract. After all potentially eligible studies were selected, 
relevant data were extracted and the methodological quality was examined. The “Strengthening the 
Reporting of Observational Studies in Epidemiology” (STROBE) statement checklist 7 was used to 
develop this data extraction form and quality assessment tool (Appendix 8). Only full articles were 
assessed for methodological quality. The following factors were addressed, depending on the type 
of study: clear definition of outcome variable, reliability of the measure of assessment, clear outline 
of the number of patients at each stage of the study, adjustment of confounders, confidence 
intervals and p-values presented. A study scored 1 point if the criterion was fulfilled, 0.5 points if it 
was partially met and 0 if it was not fulfilled. The points were then tallied and the methodological 
quality was rated accordingly, <50% (poor), 50-74% (average) and ≥75% (good). Barriers and 
facilitators were categorised according to 3 domains: psycho-social (related to a patient’s attitudes 
and beliefs), economic (related to a patient’s resources) and health systems (factors influencing 

























3.1) Characteristics of included studies 
The search yielded a total of 760 citations (Fig 3). After the first screen, 70 potentially eligible 
studies remained (54 articles and 16 abstracts). Twenty-five studies were excluded because they 
were of poor methodological quality (n=11), did not meet the inclusion criteria (n=9) and were 
inaccessible (n=5). Overall, 45 studies were retained for study analysis (36 articles and 9 abstracts). 
The majority of studies were conducted in South Africa (n=16) and the remainder were conducted 
across other parts of the region: Uganda (n=9), Kenya (n=5), Malawi (n=4), Mozambique (n=2), 
Ethiopia (n=2), Tanzania (n=2), Zambia (n=2), Rwanda (n=1), Swaziland (n=1), additionally one 
study was conducted in both South Africa and Zimbabwe. The methodological quality of most full 
text articles (n=19/36) was rated average as these studies scored between (50-70%) whereas 47% 
of studies (n=17/36) were of high quality scoring ≥75%. All studies provided an outcome definition, 
the majority used appropriate statistical tests (n=21/27) and 78% (n=21/27) adjusted for 
confounders. Common weaknesses noted in most studies were: no indication of how missing data 
was handled (n=19/27) and for a few studies, confidence intervals (n=6/27) and p-values (n=4/27) 
were not provided. Of the 8 studies that traced patients, all adequately described the method of 
follow-up except for one study 34.  
 
3.2) The proportion of patients at each step of the HIV cascade 
3.2.1) Enrolment into HIV care and completion of ART-eligibility assessment 
Twenty studies examined step 1-4 of the cascade (Fig 1A-B, Table 1). The majority of studies (n=8) 
were conducted in South Africa with the remainder scattered across the region: Uganda (n=4), 
Ethiopia (n=2) and Kenya (n=2), Malawi (n=1), Mozambique (n=1), Rwanda (n=1) and Tanzania 
(n=1). Only four studies were of good methodological quality.  
Nine studies indicated the percentage of HIV+ patients that registered at a medical facility for 
ongoing HIV care post-diagnosis. Enrolment into HIV care was assessed mainly via patient folder 
reviews and most studies did not incorporate time cut-offs in the definition of this variable. In non-
selected patients enrolment into care ranged between 47%-70% yet between 42% 10, 20 -85% 14 in 












study followed-up patients who failed to enrol in HIV care and reported that 5% of all patients were 
deceased. 9 Two studies, which were of average quality and on non-selected patients 10, 14 based 
assessments on self-reports. Due to the potential risk of social desirability bias this could have 
inflated the enrolment estimates reported in these studies. One study scored 50% for study quality 
as confounders were not adjusted for which may have lead to an overestimation of the estimates 
reported. 8 Excluding this study would not have changed the range of enrolment to HIV care 
considerably. 
Eleven studies reported the percentage of HIV+ patients that underwent ART eligibility assessment 
which was either assessed through laboratory-based CD4 count testing 15-22, and/ or WHO clinical 
staging 12. One study scored 50% for study quality as investigators did not adjust for potential 
confounders which may have lead to an overestimation of the estimates. 11 Excluding this study 
would not have changed the range of ART-eligibility assessment considerably. 
Eight studies investigated the proportion undergoing CD4 count testing (range: 55% within 8 weeks 
18-85% within 12 weeks 17) and a further two studies assessed patient return for collection of CD4 
count results (range: 85% within 8 weeks 18- 35% within 12 weeks 17).  
 
3.2.2) Retention in pre-ART care 
 Five studies investigated the proportion of ART-ineligible patients who were retained in pre-ART 
care and three used time-cut offs (Table 2). Four of these studies were from South Africa; the fifth 
study was from Malawi. Majority (4/5) were of good methodological quality. Retention in pre-ART 
care in South African studies ranged between 42% (6 months) 22-45% (13 months) 28. Retention 
was almost 2-fold greater in those with CD4 counts between 200-350 cells/µl compared to those 
with CD4 counts >350 cells/µl in a HIV clinic in South Africa. 29 However, retention in pre-ART care 
reported in rural Malawi was the highest (59%), albeit no time-cut offs were used. 30 Only one study 
traced those individuals lost to follow-up (LTFU) and found that majority LTFU (35%) were 
deceased. 30 
 
3.2.3) Linkage to ART care 
Seventeen studies investigated the proportion of ART-eligible patients who subsequently initiated 
ART (Table 3). More than two thirds of these studies were of average quality (69%). The majority 
(n=8) where conducted in South Africa whereas the remaining studies were from Kenya (n=2), 
Malawi (n=3), Uganda (n=3) and Mozambique (n=1). The median percentage of ART-eligible 
patients linking to ART care was 67% (IQR 58-81). Three studies included scored ≤60% for study 












linkage (69%) is prone to bias .13, 38-39 However, if these studies were excluded it would not have 
changed this median considerably. Almost half of the studies (n=9) failed to specify a time-cut off. 
Only one study examined linkage to ART care among children and showed that less than half of 
them initiated ART (40%). 38 The median time to ART initiation ranged from 22 days in rural Malawi 
34 to 6.6 months in two semi-private hospitals in South Africa 21. Of the eight studies indicating 
outcomes for those failing to initiate ART, death was common among these patients (3-25%).  
 
3.3) Risk factors associated with retention or attrition at each step of the HIV cascade 
3.3.1) Enrolment into HIV care and completion of ART-eligibility screening 
Four studies examined enrolment into HIV care among individuals testing HIV+ with one having 
good methodological quality (Table 4). These studies were conducted in Kenya (n=1), Rwanda 
(n=1), South Africa (n=1), and Uganda (n=1). Being male, younger age, having 1-2 co-residents, 
being married and having a high CD4 count (>250 cells/µl) decreased the likelihood of enrolling in 
HIV care after testing in a study form rural Uganda. 26 Another study in FSWs found that the risk of 
not enrolling in care increased for individuals that were breastfeeding, had a known HIV+ sexual 
partner and reported condom use in the last sex act. 14 
Studies which examined predictors for CD4 count testing (n=3) 16, 18, 22 and completion (i.e. CD4 
count testing and collection of this result) (n=2)19, 29 were all conducted in South Africa and 2/4 were 
of good methodological quality. These showed that self-referred patients, distance from clinic (≥10 
km), history of tuberculosis (TB) treatment, referral by healthcare provider for HIV testing and being 
male increased the likelihood for not undergoing CD4 count testing. 16, 18,22 Correlates associated 
with CD4 count testing and patient collection of this result were low CD4 count (351-450 cells/µl) , 
age (25-36 years), secondary schooling, the perception that people do not care what their CD4 
count result is and a CD4 count does not matter if HIV+. 19, 29 
 
3.3.2) Retention in pre-ART care 
Only one study, from South Africa, investigated factors associated with retention in pre-ART care 
among individuals not yet eligible for ART and was of good methodological quality (Table 4). This 
study found that male patients, individuals with high CD4 counts (> 500 cells/µl) and those between 
16-25 years of age were at increased risk for non-retention in care. 28 
 












Nine studies investigated determinants associated with failure to initiate ART among ART-eligible 
individuals (Table 4). Most were from South Africa (n=3) and the remainder were from Uganda 
(n=1), Malawi (n=2), Kenya (n=2). Only four were of good methodological quality. Common 
predictors for failure to initiate ART were being a man 21, 22, 35, 24, having advanced immunodeficiency 
24, 32, 35, 37 and having lower levels of education 31, 34.  
Advanced clinical stage (III, IV) was associated with death prior to ART initiation in a study 
conducted in Ethiopia which showed good methodological quality. 9 
Risk factors associated with non-linkage to ART care among ART-eligible individuals were 
assessed in two studies conducted in Ethiopia 9 and South Africa 36, with a methodological quality of 
75% and 50% respectively. These predictors were having a less advanced clinical stage (I, II) 9 
being a rural resident 9, being part of a recent cohort (2007-2008) 9, pregnancy 36 and age (< 25 
years). 36 
 
3.4) Barriers and facilitators influencing the patient continuum of care 
3.4.1) Enrolment into HIV care and completion of ART-eligibility screening 
Four studies assessed barriers to enrolment into HIV care among those who tested HIV+ and were 
conducted in Rwanda 14, Kenya 10 and South Africa 20,41 (Table 5). Perceived good health (33%) 14, 
feeling healthy (40%) 10 and being unable to get time off work (41.4%) 20 were the main reasons for 
not enrolling into care as reported among FSWs, home-based testers and mobile testers, 
respectively. A study from Tanzania, with average methodological quality, showed that a structured 
referral system, transport vouchers, community escorts and supportive counselling facilitated patient 
enrolment into HIV care. 23 Most patients who underwent CD4 count testing in a study conducted in 
South Africa reported they failed to collect their baseline CD4 count because they had insufficient 
time to do so (29%) and were unable to get time off work (19%). 19  
 
3.4.2) Retention in pre-ART care 
Only one study from Malawi, with high methodological quality, examined reasons for not being 
retained in pre-ART care among individuals not yet eligible for ART 30 (Table 5). The main reason 
(45.8%) was a psycho-social factor (HIV-related stigma). However, 20% of patients reported that 
they could not afford transport fees and nearly a third (31.6%) were dissatisfied with the care they 
received at the clinic. 30 
 












Sixteen studies examined barriers to ART initiation and more than half (63%) had good 
methodological quality (Table 5). Most studies were conducted in Uganda (n=5) whereas the 
remainder were conducted elsewhere: South Africa (n=3), Zambia (n=2), Kenya (n=1), Mozambique 
(n=1), Ethiopia (n=1), Swaziland (n=1), Tanzania (n=1), and one conducted in both Zimbabwe and 
South Africa. Lack of knowledge on antiretrovirals (ARVs) (67.2%) 45, inability to afford transport 
fees (range: 20%-93%) 24, 44, 49 and shortage of staff (96.6%) 45 were the main psycho-social, 
economic and health systems barriers, respectively.  
 
4) DISCUSSION 
This review showed that substantial attrition occurred at each intermediate step between HIV testing 
and ART initiation. The first major drop-out occurred at the point of linkage from a HIV testing site to 
a medical facility for ongoing care. Once in care, the next loss occurred between CD4 count testing 
and collection of the test result. Less than half of the ART-ineligible patients were retained in pre-
ART care (range: 42%-45 %) and nearly two-thirds of ART-eligible patients linked to ART care 
(median: 67%, IQR 58-81).  
Approximately 47%-70% of patients linked to care following an HIV+ diagnosis. Failure to enter into 
the continuum care could result in death as indicated in a study from Ethiopia.9 A study in the US 
showed that 69% of patients entered into HIV care, with most testing sites based at medical 
facilities.53 This result compares with findings in Ethiopia whereby 70% of patients diagnosed HIV+ 
within a hospital linked to ongoing HIV care at this facility.9 However, reports on linkage to HIV care 
from non-medical facilities (i.e. via home-based and mobile services) were shown to be less 
encouraging (42%) 10,20. Facilitators such as a structured referral system, transport vouchers, 
community escorts and supportive counselling could assist in a patient’s linkage as indicated in a 
study conducted in Tanzania whereby 68% of patients diagnosed HIV+ at a rural testing site 
accessed HIV care at an urban clinic. 23 A study from Uganda showed that men, younger 
individuals, being married, having 1-2 co-residents and those with high CD4 counts were more likely 
not to link to care. 26 Hence, post-test counselling should be intensified and focused at these 
individuals.  
Patients undergoing CD4 count testing ranged from 77% within 1 month in Mozambique 13 to 63% 
within 6 months in South Africa 16. Additionally, patient return for CD4 count collection varied 
between studies as a public sector clinic in South Africa showed a low return among patients (35% 
within 12 weeks of CD4 testing) 17 in comparison to two semi-private hospitals in South Africa (85% 
within 8 weeks) 18. Results from a recent study show that retention between diagnosis and 












review indicate that a substantial proportion of HIV+ patients fail to initiate and complete CD4 count 
testing and most have little time to return to the clinic for this result. 19 Studies conducted in South 
Africa and Mozambique have shown that point-of-care (POC) CD4 count testing could reduce this 
loss as most patients can undergo this procedure and receive their result within 24 hours.54-55 
Moreover, this technology could improve retention as patients who were immediately aware of this 
result were more likely to be retained in wellness or ART programmes (44%) compared to those 
who had to make an additional clinic visit for their laboratory-based CD4 count result (33%).54  
Less than half of the ART-ineligible patients were retained in pre-ART care. This result compares to 
the median proportion of pre-ART care retention (46%) reported in a recent review. 6 Pre-ART 
monitoring through CD4 count testing can ensure a gain in patient life-years due to timely initiation 
of treatment. 5 More than a third (46%) of pre-ART patients in South Africa were LTFU 22 and in 
Malawi death was a common outcome among those LTFU. 30 A pre-ART care model similar to that 
described in a recent study conducted in rural South Africa could potentially alleviate these high 
rates of LTFU as this study showed that patients receiving >6 months care from a counsellor-led 
pre-ART programme had a reduced risk for being LTFU and dying after ART initiation 56. Male 
patients, individuals with high CD4 counts and those between 16-25 years of age were more likely 
not to be retained in pre-ART care in South Africa.28 These findings underscore the importance of 
developing a pre-ART model of care that can help retain men and younger individuals as well as 
provide stronger post-test counselling to ensure patients are informed of the clinical benefits of pre-
ART care retention. Provision of the anti-bacterial drug, Cotrimoxazole, could serve as an incentive 
to retain ART-ineligible patients in pre-ART care as shown in a study conducted in Kenya.57 
The median percentage of linkage to ART care in ART-eligible patients was only 67% and delays in 
ART initiation were considerable. This result compares to the median percentage of retention 
between enrolment in ART care and ART initiation (68%) found in a recent review. 6 Even in 
paediatric care less than half of ART-eligible children linked to ART care.38 This poor linkage was 
mainly due to the socio-economic challenges faced by caregivers which suggests that these 
individuals require additional support and education on caring for HIV+ children.38 Delayed ART 
initiation increases the risk for mortality and morbidity.3 Introducing POC CD4 count testing in clinics 
could reduce these delays as a study conducted in Mozambique showed a reduction by 26 days, 
from time to enrolment to ART initiation.55 Additionally, more effective post-test counselling and 
referral systems could reduce delays and improve linkage. Research in South Africa showed that 
most deaths occurred before or during treatment readiness 35 and a low CD4 count was a predictor 
for death prior to ART initiation.9 Fast-tracking of patients has been frequently recommended to 
reduce these deaths.21,35 This strategy may reduce some early ART or pre-ART death, but the 
source of the problem lies further upstream in the cascade and hence solutions targeted at earlier 












knowledge about ARVs (67.2%) 45, inability to afford transport fees (range: 20%-93%) 24,44,49 and 
shortage of staff (96.6%) 45. These findings allude to the need for more educational programmes on 
ARVs, provision of transport vouchers, decentralisation of care and task-shifting in clinics.6, 22, 30, 56 
This review has a number of limitations. There was a high level of heterogeneity in the outcome 
definition of studies reviewed. Time-cut offs varied and most studies did not incorporate time cut-offs 
into their study design, making it challenging to compare and combine estimates. The sample size 
of some studies was small. 11,14,20,25,31 and most were of average quality. This review might be 
subject to publication bias as programs in more resource-constrained settings are less likely to be 
published. The majority of studies were from South Africa and thus our findings maybe more 
reflective of this setting. It was difficult to amalgamate data as some were focused on specific 
groups (i.e. FSWs 14, home-based testers 10, and mobile clinic testers 20) and others on specific 
settings (i.e. semi-private hospitals 21, 35 and hospital emergency departments 11). Most studies 
obtained their data from patient folders and only 2 tracked those LTFU.24, 30 It is likely those LTFU 
may have accessed care elsewhere and thus this misclassification could have inflated attrition 
estimates. Certain findings were prone to social desirability bias as some studies were based on 
self-reports only.10, 14 Some studies did not quantify respectiv  barriers and facilitators (n=10) and 
thus it was difficult to compare studies. Several factors intrinsic to linkage to HIV/ART care  in each 
country (i.e. stage of epidemic at the time of studies, the availability of ART, political commitment to 
ART) were not examined in this review and should be taken into account in future studies 
investigating linkage to HIV/ART care. 
In conclusion, findings from this review shed light on the high degree of attrition occurring at all 
steps between HIV testing and ART initiation. The first area of attrition occurred during linkage to 
HIV care after diagnosis. This could be solved through introduction of referral systems, transport 
vouchers and community escorts. Increasing the number of patients that undergo CD4 testing and 
obtain their result can be improved through POC CD4 testing, more effective post-test counselling 
or referral systems as well as notifying patients telephonically of their result. Retention in pre-ART 
care was less than 50% in four out of five studies. Pre-ART care models should be tailored to the 
needs of those at risk for defaulting care (i.e. men and younger individuals) and should include 
effective post-test counselling with greater emphasis on the importance of retention in care despite 
a high CD4 count. Delays between enrolment in ART care and initiation of ART were considerable 
which underscores the need for interventions targeted at upstream stages of the cascade 3 to 
ensure patients present early for care and are retained throughout the continuum of care. If previous 
recommendations for patient health information tracking systems 6, 17, improved monitoring and 
evaluation tools 12 and standard definition of outcomes 6, 9, 17  are met, than future studies should 
examine the flow of patients from diagnosis to ART initiation for more accurate estimates of losses 
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Fail to undergo CD4 
count testing LOSS Y 










Undergo CD4 count testing 
 
LOSS B 










 Clinical staging, checked if 
pregnant/planning to conceive, 
screened  for TB 
b




 count done 
STEP 6 
Remain in pre-ART care 
until ART-eligible 
STEP 5 
Enrolled in pre-ART care 
 
 Physical exam, CD4 count 
testing every 6 months, WHO 
f 
clinical staging, screened for TB 
symptoms, perform pap smear, 
check for OI 
g





, information and education 
session, evaluate psychosocial 
support, promote and assess 
adherence 
ART-ELIGIBLE 
 CD4 count <200cells/ µl 
irrespective of clinical stage 
 CD4 count <350cells/ µl 
- In patients with TB/HIV 
- Pregnant women 









NOT YET ELIGIBLE FOR ART 
e
 
 Transferred to a Wellness 
Programme for follow-up 
care, support and treatment 
STEP 7 
Enrolled in a Treatment 
Readiness Programme 
 (4-12 weeks) 
 
 Educate patient on their HIV 
status, ART, importance of 
adherence and regular clinic 
visits 
 Reassess ART readiness 
 Conduct physical examination 
and laboratory investigation 
 
LOSS E 





 STEP 8 
Initiate ART 
 
 Prescribe recommended 
ART regimen based on 
laboratory investigations 
 Dispense ART and detail 









Register at a HIV clinic for 
ongoing care 
Figure 1B: The flow of an HIV+ 
patient from a testing at a non-
medical site to a medical facility 
















SET   Medline and Global Health  




5 ACQUIRED IMMUNODEFICIENCY SYNDROME 
6   Set 1-5 were combined with "or" 
7 Retention PATIENT DROPOUTS  
8 LONG TERM CARE 
9 CONTINUITY OF PATIENT CARE 
10 patient dropouts 
11 long term care 
12 loss to follow-up 
13 retention in care 
14 attrition or defaulting 
15 pre-art or (pre adj1 treatment) or (art adj1 initiation) 
16 screening for art 
17 art eligibility 
18 eligible for art 
19 eligibility for art 




24 continuum of care 
25 continuity  
26   Set 7-25 were combined with "or " 
27  Set 6 and 26 were combined with “and” 
28  Set 27 was limited to years "2000-current" 
29 Country DEVELOPING COUNTRY 
30 AFRICA SOUTH OF THE SAHARA 
31 AFRICA 
32 sub-Saharan 
33  all sub-Saharan countries included as Mesh and text 
term combined with or 
34  Set 29-33 were combined with "or " 
35  Set 28 and 34 combined with “and” 
Words written in capital letters were used as MeSH headings, the 
others were used as free text.  
 
 
Figure 1A: Describing each stage along the cascade from HIV testing to treatment  
(as per South African Nation l guidelines) 4  
a=HIV positive, b=tuberculosis, c=haemoglobin, d=full blood count, e=antiretroviral therapy, f=World Health Organisation, 















































760 potentially eligible citations identified for 
screening  
- 734 potentially relevant citations 
obtained from keyword searches on 
electronic databases  
- 8 potentially relevant citations 
retrieved from reference lists  
-  18 potentially relevant citations 
gathered from conference abstracts 
Screen 1: 690 excluded  
- 169 duplicates 
-  519 irrelevant on basis 
of title and/or abstract 
- 2 conference abstracts- 
retrieved the published 
paper 
70 studies selected for full text review (54 articles + 16 abstracts) 
Screen 2: 25 excluded 
- 5 published articles were 
not freely accessible 
- 9 irrelevant to topic  
- 11 had poor 
methodological quality 
studies (4 articles + 7 
abstracts: assessment 
score < 50%) 
45 studies retained for analysis (36 articles and 9 abstracts) 


























Table 1: Enrolment into HIV care and completion of ART eligibility assessment 





Enrolled into HIV care 
as a prerequisite of 
accessing CD4 
counts 
Blood sample for 
CD4 count 
provided 
Returned for CD4 
results 
Enrolled in HIV care Quality assessment 
score 
(time cut-off) (time cut-off) (time cut-off) (time cut-off) 
Assefa[8] Ethiopia Public sector sites 2008 1314 
   




Mobile HIV testing 
service for high risk 
individuals 
2008 2035 
   
26% (2 months) 50% 
Mulissa[9] Ethiopia Urban, Hospital 2003-08 2191 
   
70% (no time cut-off, but 49% 
enrolled the same day) 
75% 
Amolloh[10] Kenya 
Asembo, Home based 
testing service 
2008-09 737 
   






87% (no time cut-
off)   
50% 
Tayler Smith[12] Malawi 
Thylo, district hospital, 
patients with clinical 
stage I or II 
2008-09 1428 
  
55% (at least 1 
months follow-up)  
70% 
Micek[13] Mozambique 
Urban, HIV testing 
services 
2004-05 7005 57% (within 30 days) 
77% (within 30 
days) of those who 




Kigali, female sex 
workers 
2007-08 141 
   
85% (no time cut off) 70% 
April[15] South Africa 
Cape Town, hospital, 
primary care clinic 
2006 375 
 
62% (within 6 
months)   
74% 
Kranzer[16] South Africa 
Cape Town, hospital, 
primary care clinic 
2004-09 988 
 
63% (within 6 
months)   
75% 





85% (within 12 
weeks) 
35% (within 12 
weeks) of those 
who underwent 
CD4 count testing 
 
70% 








55% (within 8 
weeks) 
85% (within 8 
weeks) of those 
who underwent 
CD4 count testing 
 
74% 
Naidoo[19] South Africa Johannesburg, clinic 
 
 
225   
47% (within 1 
week)  
Abstract 
Govindasamy[20] South Africa 
Cape Town, mobile 
HIV testing service 
2008-09 192 
  
73% (no time cut 
off), patients were 
notified of their 
result 
telephonically 
42% (no time cut off) of those 
who received their CD4 result 
Abstract 





69% (within 90 













Ingle[22] South Africa 




74% (no time cut-
off)   
75% 
Nsigaye[23] Tanzania Mwanza city, clinic 2005-08 349 
   
68% (no time cut-off) 61% 
Amuron[24] Uganda Jinja, clinic 2004-06 2483 
  
88% (no time cut-
off)  
70% 




   
56% (within 6 months) 70% 
Nakigozi[26] Uganda 
Rakai community 
cohort study  
1145 
   
69% (6 months) Abstract 
Wanyenze[27] Uganda Kampala, hospital 2004 211 
   




























Table 2: Retention in pre-ART care 





Retention in pre-ART a care 
Assessment of pre-
ART retention 
Comment Quality assessment score 
(time cut off) 
Lessells[28] South Africa 
Rural KwaZulu-Natal, 
public sector clinics 
2007 4223 45% (13 months) repeat CD4 count 
 
78% 
Ingle[22] South Africa 
Free State, public 
sector clinics 
2004-07 11039 42% (6 months) visits to the clinic 12% died, 46% loss to follow-up 75% 




CD4 200-350: 6% within 4 months, 
41% within 1 year 
CD4 350+: 15% within 9 months, 
26% within 1 year 
  
70% 
Kranzer[16] South Africa 
Cape Town, hospital, 
primary care clinic 




Rural Malawi, district 
hospital, clinics 
2004-07 5685 59% (no time cut-off) 
 
4% known dead, 6% transferred out, 
31% loss to follow-up (a sample of 
the patients lost to follow-up were 
traced: 26% were alive, 35% were 















Table 3: Linkage to ART care 
Author Country Setting 




Linkage to ART a 
care for those 
eligible 
Median (mean) 
time to ART 
initiation 
Comment Quality assessment score 
(time cut off) 
Karcher[31] Kenya Nyanza, district hospital 2004-05 159 78% (no time cut-off) 
 
3% died, 13% denied treatment 65% 




Thyolo, district hospital, patients 
with WHO b stage 1/2 and 
CD4<250 cells/uL 




Thyolo, district hospital, TB c 
patients 
2003-04 742 14% (no time cut-off) 
  
65% 
McGrath[34] Malawi Karango, rural, district hospital 2005-06 659 86% (no time cut off) 22 days  (12-29 ) 
5% died,  0.5% had moved, 3% alive 
not taking ART, 5% untraceable 
78% 
Micek[13] Mozambique Urban, HIV testing services 2004-05 1506 50% (6 months) 71 days 
 
60% 
Kranzer[16] South Africa 
Cape Town, hospital, primary care 
clinic 
2004-09 219 67% (within 6 months) 
  
75% 
Ingle[22] South Africa 
Free State, public sector clinics, 
eligible at first CD4 measurement 
2004-07 19089 59% (no time cut off) 95 days (53-170) 
25% died, 3% in care, 13% not in 
care 
75% 
Ingle[22] South Africa 
Free State, public sector clinics, 
eligible at subsequent CD4 
measurement 
2004-07 2994 58% (no time cut off) 
 
13% died, 19% in care, 9% not in 
care 
75% 
April[15] South Africa 
Cape Town, hospital, primary care 
clinic 
2006 72 68% (no time cut off) 
  
74% 
Bassett[35] South Africa Durban, semi-private hospitals 2006 501 81% (3 months) 
 
6% died, 3% accessed a different 
service, 0.6% moved away, 0.6% 
promised to return, 6% untraceable 
81% 
Bassett[21] South Africa Durban, semi-private hospitals 2006-08 538 39% (12 months) 6.6 months 17% died 78% 
Kaplan[36] South Africa 
Cape Town, primary care clinic, 
women 
2002-07 2131 81% (no time cut off) 
 
4% died, 7% loss to follow-up 50% 
Lawn[37] South Africa Cape Town, primary care clinic 2002-05 1235 75% (no time cut off) 34 days (28-50) 
5% died, 9% preparing for ART, 11% 
loss to follow-up 
72% 
Feucht[38] South Africa Pretoria, urban, hospital, children 2004 243 40% (no time cut off) 
  
50% 
Geng[39] Uganda Mbarara, clinic 2009-10 697 58% (3 months) 
  
53% 
Amuron[24] Uganda Jinja, clinic 2004-06 2182 85% (no time cut- off) 33 days (15-406) 
Survival status was investigated for 
all losses between testing and 
treatment (included losses of patients 
not returning for their CD4 result): 7% 
died, 8% on ART with a different 
provider, 6% were alive and not on 














NGOs d and governmental health 
units 

































Table 4: Factors influencing the patient continuum of HIV care 










Not enrolling in 
HIV care* 






Not retaining in 
pre-ART a care* 
Not initiating ART* 




to ART care 
Mulissa[9] Ethiopia Urban, Hospital 2003-08 2191      











(I, II), rural 
resident, part 












Enrolling in care 
Older age, female, 
HIV disclosure, 
perceived poor 




enrolled in care 




2004-05 159     
Treatment denial 
Pregnancy, lower level 
education 




2005-08 2471     
Age (<35 years), 
severe malnutrition, 











known HIV+ d sexual 
partner, reported 
condom use in the 
last sex act 



































Having a repeat 
CD4 count 
Age (≥ 30 years, 
VCT e clients) 






2008-09 416   
Low baseline CD4 
count (351-450 
cells/µl), employed 




























 CD4 count 
collection 




people do not care 
what their CD4 
count result is, 
CD4 count does 
not matter if you 
are HIV+ 








Enrolling into care  
Low CD4 count 
(≤350 cells/µl),  
disclosure, presence 





Low CD4 count 
(≤350 cells/µl), 
being female, the 
availability of a 
phone number  







2006-08 1474     
Men, patients with no 
family/friends who 
were HIV-infected 












Men, enrolled in a 
rural clinic, clinic with 
low staffing levels, 

















national ID f 
number 







2006 501     
Male, unemployed, 
baseline CD4< 100 
cells/µl 







2002-07 2131       
Pregnancy, 









2002-05 1235     
Advanced 
immunodeficiency 







2007 4223    
High CD4 count  
(> 500 cells/µl), 
male, young age 
(16-25 years) 











CD4> 250 cells/µl 
      Abstract 
Amuron[24] Uganda Jinja, clinic 2004-06 2182     
Incomplete 
screening 
Male, low CD4 count 
(<50 cells per 106/l) 




2005-06 659     
Less education, 
difficulty dressing, 
more delayed ART 
initiation appointment, 
mid-upper arm 
circumference < 22 
cm 





2003-04 742     
Non-acceptance to 
ART 
Cost of transport to 
ART site 





*= as per sub-heading unless otherwise stated 






























Urban-Kigili, VCT a 
clinic. FSWs b 
Enrolment into 
HIV care 
Perceived good health (33.3%) 
High CD4 count at diagnosis* 







Nsigaye[23] Tanzania Mwanza city, clinic 
Enrolment  into 















Still felt healthy (44%) 
Did not believe HIV test result 
(22%) 










Cape Town, mobile 
HIV testing service 
Enrolment into 
HIV care 
Fear toxicity and side-effects of 
ART (12.6%) 
Fear of disclosure of one’s HIV+ 
status/stigma associated with 
being HIV+ /social isolation 
(8.8%) 
Work during the day 
and cannot get time off 
(41.4%) 










high risk women 
Enrolling into 
HIV care 




Long waiting time* 












Insufficient time to return to the 
clinic for result (29%) 
Difficult to get time off 
work (19.6%) 
Difficulty with transport 
costs and distance to 










those LTFU e 
HIV-related stigma (45.8%) 
Perception of health improvement 
(28.9%) 
Lack of support by partner 
(13.9%) 
Opting for traditional medicine 
(9.2%) 
Poor health (4.6%) 
Fear drug toxicities (1.3%) 
Cannot afford transport 
costs (20.1%) 
Dissatisfied with care/staff 
behaviour (31.6%) 
Inconvenient clinic hours 
(5.9%) 

























Distance from home to 
the health facility  
Food resources 
Shortage of HCWs f # 
45% 
Long waiting time for CD4 
count result # 45% 
Lack of community 







Iganaga, pre-ARV g 
clinic 
ART initiation 
Fear of being beaten or divorced 
by one’s husband* 
Lack of incentives to seek pre-
ART care* 
Cannot afford transport 
costs* 










Rural and urban- 
Kabarole, PMTCT h 
clinic 
ART initiation 
Perceived that ART should be 
commenced when bedridden  
(60%) 
Non-disclosure of HIV+ i status 
(18.9%) 
HIV-related stigma*  
 




Long waiting times* 









Lack of knowledge on ARVs 
(67.2%) 
Fear to be seen at the clinic 
(66.1%) 
Do not know if it is HIV/AIDs-think 
they are bewitched (17.2%) 
Fear side-effects of drugs 
(19.3%) 
 
Long distance to 
treatment centres 
(50.5%) 
Lack of food (24.5%) 
Not aware of free-ARVs 
(18.8%) 
Shortage of staff (96.6%) 








urban, ART clinic 
ART initiation 
Not ready to start ART (7%) 
Experiences difficulty in 
disclosing HIV status (4%) 
Requested to be referred to a 
clinic nearer ones home but failed 
to turn up for treatment (4%) 
Wants to complete TB j treatment 
before starting ART (3%)  
Fear toxicity and side-effects of 
ART (1%) 
Failed to identify a treatment 
buddy and did not return to the 
clinic (1%) 
Cannot afford transport 





Rural, NGO k 
health units 
ART initiation 
Medically unfit (10.5%) 
Uncertain about which service 
provider to choose (10.0%) 
Difficulties in understanding 
(6.7%) 




























Mshana[46] Tanzania Rural, VCT clinic ART initiation 
HIV-related stigma* 
Reluctant to identify a treatment 
buddy* 
 
Cannot afford transport 
and food costs* 
  
Confusing hospital set-up* 













on ART  & HBC 
(patients who did 
not initiate ART) 
ART initiation 
HBC patients: HIV-related stigma 
(54%) 
Don’t have time to get to the clinic 







The clinic is too far to 
travel to (27.4%) +, 
(41.3%) ++ 
Difficult to get to the 
clinic (17%) +, (21.6%) 
++ 
Can’t leave work to get 
to the clinic (13.8%) +, 
(6.9%) ++ 
 
Have to/may have to: 
Pay to travel to the 
clinic (48.2%) +, 
(14.7%) ++ 
Visit the clinic more 
than once a month 
(31.2%) +, (26.3%) ++ 
Pay someone to take 
over tasks (13.5%) +, 
(2.5%) ++ 
Pay a fee at the clinic 
(9.5%) +, (4.5%) ++ 
Accrue other costs  
(12.0%) +, (13.6%) ++ 
Spend the night away 
from home (0.7%) +, 
(2.0%) ++ 
 
Convenience of clinic 
hours ^ (77%) +, (66.3%) 
++ 
Counselling ^ (56.0%) +, 
(73.5%) ++ 
Provider time ^ (45.5%) +, 
(75%) ++ 
Service ^ (40.5%) +, (85%) 
++ 
Staff concern ^ (37%) +, 
(74%) ++ 











Consider ART to be bad (93.6%) 
Fear side effects and stigma 
(70.2%) 
Do not know much about HIV 
(46.8%) 
Scared of ending marriage 
(31.9%) 
Failure to accept status (23.5%) 





















Rural, public sector 
hospitals 
ART initiation 
Non-disclosure to partner (6.7%) 
 
Cannot afford transport 
costs (20%) 
Difficulty to get time off 
work (13%) 














Fear of taking medication on an 
empty stomach* 
Fear side-effects of medication* 
Fear disclosure and possible 
repercussions* 
Concern for continuity of care and 
treatment* 
Seeking alternate care* 
Conflicting information from 
religious/community leaders* 






Rural and urban, 
public sector sites 
ART initiation 
HIV-related stigma* 
Perceived good health* 
Opting for traditional medicine* 
Fear side-effects of drugs* 
 
Cannot afford transport 
fees* 











rural, HIV clinic 


























Social problems (17.3%): 
(Caregiver’s refusal to disclose 
HIV status to another adult, 
denial of child's status/ill 




Referral to other ART 
site (3.0%) 
Lack of human resources 
(20.3%)  













Bianchi[52] South Africa 
Primary healthcare 
clinics, ART clinic 
ART initiation 
 
Unable to take time off 




$= percentages may not add up as reasons such as “no reason”, “other”, “patient refused” were not presented, *=percentage not reported, #= Patients were asked to score each factor. Factors scoring <50% were regarded as barriers. 
+=HBC urban patients, ++=HBC rural patients, ^= patient’s rating of each factor 
a=voluntary counselling and testing, b=female sex workers, c=home-based care, d=antiretroviral therapy, e=lost to follow-up, f=healthcare worker, g=antiretrovirals, h=prevention of mother to child transmission, i=HIV positive, 
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f AX: 10UI UJ..OIIl 
Our _ Und .... Ga l! 8e1d<~r 
"0' CltlMrlne M.lttlews 
Danhini Govind~aort'f 
liE, Llrtm, [9 c.orr; fo>m HiV resl;"" .",d C<><m<tW"" '0 eec, 
PAGE 81 
Dopartement van GesondhaId 
Of!plIrtment of H"alth 
ISebe lezeMpilo 
nuk yeu for • .,bmlttin. veur prop .... l to und~rtalte 1M abo .... ·mentlo~td .lu <IV. We are ~I ... ed 10 Inform 'o'Ou till'll'" 
d~~."'n""l h'" . r .... led you apprOVOlI for your re<eart:h. PI"".~ «I"t8<;t tIIa followi" , people to ' Uisl you ,..;tII .. ~" 10: 
Delfl 'HC 
C_. CHC 
Mr laco v' n H-clen TRi, IOUI9w:un 
M r Dowid Binr. Td: 10211 ~a6 1119 / <IlI5 02 60 
Xind", enou .. !:hfl Ihe ' ''!Iowm, ' .. Klhered t": 
I . .....r..,.~mgnU <;;In be maoX with m. nllle<>. pre"din, !:h I t norm" Ktivlties I I .. ~""'t.o;l I .. ilitl" Ire 1'101 
Int ... r.,pled. 
2. Rflearch • ..,. In KCI!uln! ~nd.r h,,'ttI fKilitles, .r. "'pressln! con.Onl to provide _ department with an 
elect' ,,"ic COIIV of the fin.1 report w~h in 5/Ic month. of completion 01 researd!. This u n b. , " bml"ed 10 t h. 
",ovi r.ci.r ~ . .... rch Co--"rdin~Dr Chejlth ru@pgwq tOY.lI). 
3. l'I\e rd . .. n~ numbl!< all"... shou ld be " uott<:!;.,.11 ' uture COIT • • !>.",d..,.,,,,,. 
We look lorward 10 hearine lrom ""., . 
,,~ " -
DR J  
DEPUTY-DlIIECTtIR GEN ~AAt. 
DISTRICT HEAL nl S£RVICa AND PROGRAMMES 
DATI: 22 · <!:I~ . 2.0 ,0 
CC, DR •• ClAASSfN 
DR L. arTALD 
Pogo lot 2 
DIRECToR: KUPfOHTEIN"jMITCIiEU' S PlAIN SU8-5llIUCTURES 
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 ( 6 '$6(..#/,, ''  $' ,' .'0 %'#1
. #!% ( 6'$6(#00$''  
/;III " tilt _ I.'UI S6IlU"1 SW u.,.: .. 
~-11 _ &0.._ c._., 
'O .... ,.&o:>oT_ ... 
_ IotOtM_ 
'.a' __ 
Cool OIl 111 1711 r ... a,.~ _ £_--.... = ..... ---... .. ~ 
-·1_ ...... _ .. 
-~, 
~O .... ". bIooT _ _ 
'.00"_ .... _111._ ... 
Cot 0112. 11'11 
_ 011 <11·_ 
--" .~ _*,,-101» ...... 110"_ 
'.01100.»"., 
1ot000 _ nll 
, ... or U '","" 
I_ .... ___"-....... _E~ ............ __ 
C ITY HEA LT H -Olr_" 
... : R .... rch Propo-..' : L inkage to Ca •• : From HIV testing ;lind coun."lIIng 10 c: ..... (to No : '0174) 
Dea. Pro ' 8 eltkllf 
Peorm,,~ nas been granted lor you to do IIle research a5 leI oul In 10ur pr01QCOI al It.. ICIIIowong City 
Heahh C Wnics 
SO .... h .... Sub Dlatricl: 
Conblct People: 
Kllpfonte ln Sub OI'lri<:\: 
Cont.ac:t People: 
HaUl Bay Main Rd. Maslph ..... elele & LOI"'$ RNa. Clin iQ 
Mrs L 8akana (Sub O'Iin<:1 M'lnilger) 
Tel (021)710-8295 1 083333"~2 
Mrs B van N oekerlo: (Head PHC & Programme.) 
Tel t02 ' P'G-9383 / 082a2173&1 
Vuyanl , Ny.nus & U .. lncldlM Clinic:. 
Mr K N~oI<.o (Sub D,. 1rict Manager, 
Tel- (02 1jBJD-tM7 / 082 <1331 332 
M, T Jant,liel (Head P HC 4. prog.ammlll ) 
Tel. (02 1) 630-1626 101142200133 
All ,nd ,,,,Oua l patient Information obt8lned mus ' be kePI confidentta l 
2 Aor;ess 10 cllnocs and 1111 pallent! mu. be arTlfnged with 1M r.levant "'ar\llfge ... such lnal nOlTTlal 
iIdMIin are nol dl$nJp.ed 
3 A COllY at IhtI lonal repllrl mot;l be SM.'II C,ly Heall h Head OtIlee (P 0 Bo_ 21115. C ape Town 11001) 
Wlt!1 .. 3 month. 01 its compiet'orl and feedback mYS. lliso De g lAIn to."- d ,noer, Involved. 
4 YOUf prOjeCt has been gIVen an 10 numbef (1017.) PIfIn. use thl' fn any lutull! correspondence with ., 
Thank roo for your c:o-operallon ;lOCI pleas .. eontact me ~ ~oo requ ire any ftM'ther informatIOn or asslsl,m;e 
Yours U'lC8reI1 
~A1 J~ 
DR G H V~t/t:.JV../O 
MANAGER; SPEC.AUSEO HEALTH 
cc. Mrs Bakana & Mrs y,n N ... kerl< 
1..' , Nkol<o & Ms Janljit!! 
Or J enn'ng' 
1.4, Calowaol 
Plof C Mathews 
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. #!% ( 6'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#00$''  
em " can " .. 'l'IlU sut .. ,. , I ... ... .. 111 
C I TV KE"l T H 
2010 -0 7-0 2 
<~-'1 ......... \100_ 
C- ' _I'.II' .0 .... , '""' __ 
..... .. r ~GM .... _ 
' ' ' GoI , o.;o.llTl! 
CloI::_MIJ" 
'" on '1W"" f -... .. _ _ ~ __ .. ----..... -
......... '2 ____ • 
c.o' __ ' 
.o ..... !. c.o' __ 
C .."_GM ,,,_ 
~m' .... (>011 __ ..... 
' ..... W,Q>_ 
_ ._~...,.TOI"..".. 
......... __ 11 
-~, 
-,.~-=--v.. .. Dr G ~_ .. 
' .. "',- , 
$01" ... * .... 
~ .... Q1IQ---
re: Pennl •• ion to acce •• Clinic F~der Revle ... for Study 1017-4 (Linkage to ce re: From HIV 
Te.tlng and Counselling to Care) at 11 addi tional sites 
Dear Darsl1 ln i, 
PermIssion has been granted for you to ac;c:;eu 11 additiOnal City Hea lth Cl in ics. 
, . Western Sub District : 
Contacl People 
2 Mlteh"U. PI.ln Sub Distric t : 
Conlact people 
3 . Tygerberg Sub District: 
C ontact People 
-4 E.stern Sub Dis tr ict : 
C ontact People 
5 Southern Sub District : 
Conlacl People 
6 . Kllpfontein Sub Dis trict: 
Contacl People 
Albow Garden s and Langa Cli nics 
Mra M Sifanelo (Sub District Ma nager) 
Tel. (021} 514-41 22 10846302903 
M rs M Stanley (Head' PHC & Programmes) 
Tel: (021)51-4-4124 / 072329 6 361 
C rossroads, Mzamomhle and Wsltellredl!n Clinics 
Mrs 5 Elloker (Sub Disl rict Manager) 
Tel; (021) 391-50 12 / 084 222 1476 
Ms N NQana (Head PHC & Programmes) 
Tel: (021) 391 -0175 1 072 906 2540 
OelftCllnic 
Mrs Merle Alexander (Sub Distri ct Manag er) 
Tel. (02 1)936--8279 1 084 222 1471 
Mrs D Titus (Head, PHC oS. Programmes) 
Tel: (021) 938-8281 1 0&4 308 0596 
Dr Ivan Toms C linic 
Of" P Nkurunziza (Sub DI. trict Manager) 
T el: (021 ) 850-43 15 / 084 800 064-4 
Mrs N MgQweto (H ead: P HC & Prog rammes) 
Tel: (021) 850-431 2 / 084 222 1487 
Ocean View . Retreat, Kllp R~d CllnlCA 
Mrs L Bakana (Sub District M arilige r ) 
Te l. (021) 7t 0-8295 1 083 333 4942 
M rs B lIao Niek eJ1( (Head PHC 8 P rogrammes) 
Tel: (021)7 10-9383 / 08282 1 7361 
Silller10wn Clin ic 
Mr K NkOko (Sub DistriCl Maoager) 
T el; (02 1) 630-1667/ 082 4 33 1332 
Mrs T Nojaholo (Head: PHC & Programmes) 
T e l: (02 1) 630-1626 1 084 2200133 
Thank you for your co-operatIon and please contact me if you require furtl1er assistance or 
informatloro 
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